Search clinical trials for: Toripalimab plus Nab-Paclitaxel /- cisplatin

Total 1747 results

Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Sun Jing

Not yet recruiting

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Locally Advanced Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.

Recruiting

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

METASTATIC CERVICAL CANCER

China
The First Affiliated Hospital with Nanjing Medical...
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Fudan University

Unknown

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Breast Cancer

France, United States, Spain, United Kingdom, Australia
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)

Advanced or Metastatic Solid Tumors

Chile, Hungary, Korea, Republic of, South Africa, Spain, Japan
Baylor Research Institute

Completed

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Metastatic Breast Cancer

United States
Erasme University Hospital
Jules Bordet Institute; University Hospital St Luc, Brussels; Belgian Group of...

Recruiting

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma (STEREOPAC)

Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Pancreatic Neoplasm

Belgium
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Staging IV NSCLC

China
Laekna Limited

Recruiting

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Cervical Cancer | Esophageal Cancer | NSCLC | Solid Tumor | Endometrial Cancer | Gastric and Gastroesophageal Junction Adenocarcinoma

China
Spanish Cooperative Group for the Treatment of...

Completed

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (SEQUENCE)

Metastatic Pancreatic Adenocarcinoma

Spain
Mei Shi

Unknown

Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer

Cervical Cancer | Toxicity Due to Radiotherapy

China
Ruijin Hospital

Not yet recruiting

Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma (TiTanec)

Cervical Squamous Cell Carcinoma

China
Fudan University

Completed

A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer

Metastatic Breast Cancer

China
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Amgen

Recruiting

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

United States
Boston Scientific Corporation

Terminated

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Esophageal Cancer | Squamous Cell Carcinoma | Adenocarcinoma of the Esophagus

United States, India, Czechia, Poland
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Esophageal Cancer

Canada, United States
Shanghai Yizhong Biotechnology Co., Ltd.

Unknown

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Non-Small Cell Lung Cancer(NSCLC)

China
Sun Yat-sen University

Not yet recruiting

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Breast Adenocarcinoma | Inflammatory Breast Carcinoma

United States
AnewPharma

Unknown

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

Small Cell Lung Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
Washington University School of Medicine

Completed

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Adenocarcinoma | Pancreatic Neoplasms

United States
GlaxoSmithKline

Completed

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Cancer

United States, Korea, Republic of, Canada, France
Hebei Medical University Fourth Hospital

Enrolling by invitation

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Breast Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Wu Jun

Not yet recruiting

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Adenocarcinoma | Gastric Cancer | GastroEsophageal Cancer

China
Xijing Hospital

Not yet recruiting

Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer

Breast Cancer
DualityBio Inc.
BioNTech SE

Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

United States, China, France, Australia
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Chinese PLA General Hospital
Wuxi Sinotide New Drug Discovery Institutes

Recruiting

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer (HIFU)

Breast Cancer | TNBC - Triple-Negative Breast Cancer
National Cancer Institute, Slovakia

Completed

First Line TIP in Poor Prognosis TGCTs. (TIP)

Germ Cell Tumor

Slovakia
EQRx International, Inc.

Terminated

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NSCLC

United States
Huazhong University of Science and Technology
Qilu Hospital of Shandong University; Hunan Cancer Hospital; The Third Xiangya... and other collaborators

Recruiting

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

Cervical Cancer | Uterine Cervical Neoplasms

China
Memorial Sloan Kettering Cancer Center

Completed

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Bladder Cancer | Urethral Cancer

United States
Guizhou Medical University

Unknown

Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC

Efficacy and Safety

China
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Triple Negative Breast Cancer

United States, Australia
Sun Yat-sen University

Recruiting

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) (EC-CRT-006)

Esophagus Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal-junction Cancer

China
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Squamous Non Small Cell Lung Cancer

China, Turkey, United States, Georgia, Poland, Russian Federation, Ukraine
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Beijing Municipal Science & Technology Commission

Unknown

A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin

Esophageal Cancer

China
Sun Yat-sen University

Recruiting

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation (BCIRT-01)

Muscle-Invasive Bladder Carcinoma | Radiotherapy | Programmed Cell Death Protein 1 Inhibitor

China
Wei Ren

Recruiting

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China

3

Subscribe